Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 40 | 2017 | 264 | 8.010 |
Why?
|
| Cocaine-Related Disorders | 18 | 2016 | 106 | 4.960 |
Why?
|
| Dopamine Uptake Inhibitors | 17 | 2017 | 120 | 3.790 |
Why?
|
| Self Administration | 33 | 2017 | 296 | 2.690 |
Why?
|
| Receptors, Dopamine D2 | 10 | 2017 | 80 | 2.590 |
Why?
|
| Receptors, Dopamine D3 | 6 | 2017 | 33 | 1.990 |
Why?
|
| Choice Behavior | 9 | 2017 | 83 | 1.870 |
Why?
|
| Dose-Response Relationship, Drug | 28 | 2019 | 641 | 1.840 |
Why?
|
| Animals | 61 | 2019 | 7297 | 1.770 |
Why?
|
| Macaca mulatta | 26 | 2019 | 322 | 1.740 |
Why?
|
| Social Dominance | 5 | 2017 | 18 | 1.650 |
Why?
|
| Conditioning, Operant | 10 | 2011 | 96 | 1.510 |
Why?
|
| Hierarchy, Social | 6 | 2017 | 24 | 1.510 |
Why?
|
| Macaca fascicularis | 20 | 2017 | 389 | 1.500 |
Why?
|
| Ethanol | 3 | 2017 | 185 | 1.450 |
Why?
|
| Behavior, Animal | 12 | 2010 | 264 | 1.430 |
Why?
|
| Central Nervous System Stimulants | 4 | 2016 | 74 | 1.420 |
Why?
|
| Reinforcement Schedule | 12 | 2016 | 60 | 1.230 |
Why?
|
| Dopamine Agents | 3 | 2015 | 19 | 1.210 |
Why?
|
| Feeding Behavior | 6 | 2016 | 159 | 1.180 |
Why?
|
| Menstrual Cycle | 4 | 2018 | 36 | 1.140 |
Why?
|
| Alcohol Drinking | 2 | 2019 | 244 | 1.110 |
Why?
|
| Male | 46 | 2019 | 17807 | 0.930 |
Why?
|
| Yawning | 4 | 2017 | 8 | 0.910 |
Why?
|
| Dextroamphetamine | 3 | 2013 | 10 | 0.870 |
Why?
|
| Receptors, Opioid, mu | 3 | 2019 | 51 | 0.870 |
Why?
|
| Buprenorphine | 2 | 2019 | 18 | 0.830 |
Why?
|
| Positron-Emission Tomography | 10 | 2012 | 172 | 0.830 |
Why?
|
| Caudate Nucleus | 5 | 2017 | 23 | 0.780 |
Why?
|
| Dopamine Antagonists | 4 | 2017 | 23 | 0.750 |
Why?
|
| Housing, Animal | 5 | 2015 | 23 | 0.750 |
Why?
|
| Dopamine Agonists | 5 | 2015 | 28 | 0.710 |
Why?
|
| Receptors, Opioid | 1 | 2019 | 38 | 0.670 |
Why?
|
| Dopamine | 4 | 2015 | 226 | 0.650 |
Why?
|
| Discrimination Learning | 4 | 2011 | 20 | 0.640 |
Why?
|
| Substance-Related Disorders | 4 | 2017 | 113 | 0.630 |
Why?
|
| Disease Models, Animal | 8 | 2017 | 980 | 0.600 |
Why?
|
| Drug Discovery | 2 | 2016 | 30 | 0.600 |
Why?
|
| Norepinephrine | 2 | 2015 | 73 | 0.560 |
Why?
|
| Morpholines | 1 | 2016 | 34 | 0.560 |
Why?
|
| Piperazines | 4 | 2012 | 56 | 0.550 |
Why?
|
| Learning | 3 | 2015 | 76 | 0.550 |
Why?
|
| Buspirone | 1 | 2015 | 3 | 0.530 |
Why?
|
| Brain | 6 | 2017 | 930 | 0.530 |
Why?
|
| Phenmetrazine | 1 | 2015 | 4 | 0.530 |
Why?
|
| Methamphetamine | 3 | 2014 | 18 | 0.520 |
Why?
|
| Benzamides | 6 | 2017 | 54 | 0.510 |
Why?
|
| Methylphenidate | 2 | 2013 | 36 | 0.510 |
Why?
|
| Putamen | 5 | 2017 | 25 | 0.510 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 59 | 0.500 |
Why?
|
| Cognition | 2 | 2015 | 526 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 464 | 0.480 |
Why?
|
| Stress, Psychological | 3 | 2012 | 208 | 0.460 |
Why?
|
| Quinolones | 1 | 2012 | 6 | 0.450 |
Why?
|
| Primates | 8 | 2018 | 100 | 0.420 |
Why?
|
| Behavior, Addictive | 3 | 2007 | 29 | 0.420 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 5 | 2011 | 14 | 0.420 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2011 | 15 | 0.420 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 239 | 0.390 |
Why?
|
| Exploratory Behavior | 2 | 2010 | 30 | 0.390 |
Why?
|
| Tropanes | 1 | 2010 | 9 | 0.380 |
Why?
|
| Vaccination | 1 | 2011 | 123 | 0.380 |
Why?
|
| Reward | 1 | 2010 | 63 | 0.370 |
Why?
|
| Drug Interactions | 6 | 2015 | 80 | 0.360 |
Why?
|
| Hydrocortisone | 2 | 2009 | 61 | 0.350 |
Why?
|
| Serotonin | 5 | 2008 | 35 | 0.350 |
Why?
|
| Raclopride | 2 | 2005 | 8 | 0.350 |
Why?
|
| Receptors, Dopamine D1 | 2 | 2010 | 19 | 0.340 |
Why?
|
| Saimiri | 8 | 2017 | 8 | 0.340 |
Why?
|
| Testosterone | 1 | 2009 | 47 | 0.330 |
Why?
|
| Corpus Striatum | 2 | 2005 | 60 | 0.330 |
Why?
|
| Receptors, Dopamine | 3 | 2015 | 20 | 0.320 |
Why?
|
| Eating | 2 | 2019 | 73 | 0.290 |
Why?
|
| Follicular Phase | 3 | 2018 | 9 | 0.280 |
Why?
|
| Pyridines | 2 | 2017 | 78 | 0.280 |
Why?
|
| Quinpirole | 3 | 2015 | 15 | 0.280 |
Why?
|
| Luteal Phase | 3 | 2018 | 22 | 0.280 |
Why?
|
| Time Factors | 8 | 2011 | 2001 | 0.280 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2005 | 1 | 0.270 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2005 | 4 | 0.270 |
Why?
|
| Catheters, Indwelling | 2 | 2016 | 40 | 0.270 |
Why?
|
| Administration, Oral | 2 | 2016 | 169 | 0.260 |
Why?
|
| Membrane Transport Modulators | 1 | 2004 | 4 | 0.250 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 34 | 0.250 |
Why?
|
| Social Behavior | 2 | 2016 | 67 | 0.250 |
Why?
|
| Receptors, Serotonin | 2 | 2002 | 6 | 0.250 |
Why?
|
| Injections, Intravenous | 4 | 2013 | 73 | 0.250 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 97 | 0.240 |
Why?
|
| Food | 3 | 2013 | 41 | 0.240 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 118 | 0.240 |
Why?
|
| Piperidines | 4 | 2010 | 125 | 0.210 |
Why?
|
| Alanine | 1 | 2002 | 27 | 0.210 |
Why?
|
| Brain Chemistry | 1 | 2002 | 30 | 0.210 |
Why?
|
| Progesterone | 2 | 2015 | 80 | 0.210 |
Why?
|
| Opioid Peptides | 2 | 2018 | 28 | 0.200 |
Why?
|
| Dominance-Subordination | 2 | 2012 | 15 | 0.200 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 3 | 2011 | 16 | 0.200 |
Why?
|
| Serotonin Antagonists | 1 | 2000 | 5 | 0.190 |
Why?
|
| Aza Compounds | 1 | 2000 | 3 | 0.190 |
Why?
|
| Spiro Compounds | 1 | 2000 | 8 | 0.190 |
Why?
|
| Ligands | 3 | 2018 | 81 | 0.190 |
Why?
|
| Benzazepines | 3 | 2011 | 22 | 0.190 |
Why?
|
| Drug Tolerance | 2 | 2019 | 36 | 0.180 |
Why?
|
| Hallucinogens | 3 | 2008 | 11 | 0.180 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2010 | 88 | 0.180 |
Why?
|
| Azabicyclo Compounds | 1 | 2019 | 12 | 0.170 |
Why?
|
| Naltrexone | 1 | 2019 | 38 | 0.170 |
Why?
|
| Female | 10 | 2018 | 18164 | 0.170 |
Why?
|
| Microdialysis | 3 | 2004 | 33 | 0.160 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2012 | 96 | 0.160 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 246 | 0.160 |
Why?
|
| Analysis of Variance | 4 | 2012 | 454 | 0.160 |
Why?
|
| Temperature | 2 | 2007 | 55 | 0.150 |
Why?
|
| Motivation | 2 | 2008 | 102 | 0.150 |
Why?
|
| Social Environment | 2 | 2008 | 75 | 0.150 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 85 | 0.140 |
Why?
|
| Recurrence | 2 | 2015 | 235 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2016 | 21 | 0.140 |
Why?
|
| Models, Animal | 2 | 2014 | 160 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2009 | 1218 | 0.130 |
Why?
|
| Estradiol | 1 | 2015 | 118 | 0.120 |
Why?
|
| Humans | 9 | 2017 | 29093 | 0.120 |
Why?
|
| Pain | 1 | 2016 | 282 | 0.120 |
Why?
|
| Radioligand Assay | 2 | 2010 | 23 | 0.120 |
Why?
|
| Fluorine Radioisotopes | 2 | 2010 | 21 | 0.120 |
Why?
|
| Drug Partial Agonism | 1 | 2012 | 3 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 747 | 0.110 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2009 | 22 | 0.110 |
Why?
|
| Dexamethasone | 2 | 2009 | 42 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2011 | 13 | 0.100 |
Why?
|
| Nicotinic Agonists | 1 | 2011 | 48 | 0.100 |
Why?
|
| Rats | 1 | 2015 | 1604 | 0.100 |
Why?
|
| Pregnancy, Animal | 1 | 2010 | 19 | 0.090 |
Why?
|
| Haplorhini | 2 | 2011 | 64 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2011 | 141 | 0.090 |
Why?
|
| Magnetoencephalography | 1 | 2009 | 13 | 0.090 |
Why?
|
| Somatosensory Cortex | 1 | 2009 | 26 | 0.090 |
Why?
|
| Pituitary-Adrenal System | 1 | 2009 | 24 | 0.090 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2009 | 34 | 0.090 |
Why?
|
| Blinking | 2 | 2010 | 5 | 0.080 |
Why?
|
| Thermogenesis | 1 | 2008 | 4 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3099 | 0.080 |
Why?
|
| Thyroxine | 1 | 2008 | 16 | 0.080 |
Why?
|
| Brain Mapping | 1 | 2009 | 182 | 0.080 |
Why?
|
| Cerebellum | 1 | 2008 | 29 | 0.080 |
Why?
|
| Hyperalgesia | 2 | 2019 | 88 | 0.080 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 1 | 2007 | 2 | 0.080 |
Why?
|
| Gyrus Cinguli | 1 | 2007 | 22 | 0.080 |
Why?
|
| Extinction, Psychological | 1 | 2007 | 19 | 0.080 |
Why?
|
| Fever | 1 | 2007 | 56 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2005 | 15 | 0.070 |
Why?
|
| Autoradiography | 1 | 2005 | 47 | 0.070 |
Why?
|
| Sex Factors | 3 | 2012 | 631 | 0.070 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 25 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2004 | 55 | 0.060 |
Why?
|
| Neostriatum | 1 | 2004 | 21 | 0.060 |
Why?
|
| Quipazine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2002 | 35 | 0.050 |
Why?
|
| Homovanillic Acid | 2 | 2012 | 11 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 836 | 0.050 |
Why?
|
| Body Temperature | 2 | 2014 | 22 | 0.050 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2000 | 3 | 0.050 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2000 | 37 | 0.050 |
Why?
|
| Hydroxyindoleacetic Acid | 2 | 2010 | 17 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 58 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2019 | 124 | 0.040 |
Why?
|
| Oxycodone | 1 | 2018 | 7 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2019 | 95 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 82 | 0.040 |
Why?
|
| Drug Design | 1 | 2018 | 44 | 0.040 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 50 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 519 | 0.040 |
Why?
|
| Morphine | 1 | 2018 | 57 | 0.040 |
Why?
|
| Appetitive Behavior | 2 | 2008 | 6 | 0.040 |
Why?
|
| Food Preferences | 2 | 2008 | 35 | 0.040 |
Why?
|
| Pregnancy | 2 | 2010 | 815 | 0.040 |
Why?
|
| Motor Activity | 2 | 2010 | 310 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 61 | 0.030 |
Why?
|
| Glucose | 1 | 2016 | 163 | 0.030 |
Why?
|
| Animal Experimentation | 1 | 2014 | 6 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2014 | 167 | 0.030 |
Why?
|
| Species Specificity | 1 | 2012 | 84 | 0.030 |
Why?
|
| Mecamylamine | 1 | 2011 | 13 | 0.030 |
Why?
|
| Nicotinic Antagonists | 1 | 2011 | 19 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2009 | 6 | 0.020 |
Why?
|
| Nicotine | 1 | 2011 | 157 | 0.020 |
Why?
|
| Benzylamines | 1 | 2008 | 3 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2008 | 7 | 0.020 |
Why?
|
| Fingers | 1 | 2009 | 57 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2009 | 102 | 0.020 |
Why?
|
| Reaction Time | 1 | 2008 | 121 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2008 | 42 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2008 | 67 | 0.020 |
Why?
|
| Association Learning | 1 | 2007 | 16 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 33 | 0.020 |
Why?
|
| Deoxyepinephrine | 1 | 2007 | 2 | 0.020 |
Why?
|
| Serotonin Agents | 1 | 2007 | 5 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2008 | 149 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 242 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 353 | 0.020 |
Why?
|
| United States | 1 | 2014 | 3630 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2000 | 106 | 0.010 |
Why?
|